Infliximab | Health Canada Patents | Expiry | Expiration | Dates | PharmaCompass.com

Please Wait

Applying Filters...

Grow Your Pharma Business Digitally

Find Suppliers : API/FDF
- Search Our Integrated Database
Services
Excipients
CDMO Prospector
- Demo Dashboard
Drugs in Dev.
News
Blog
Market Place
Login

Infliximab
Health Canada Patents

Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

Contact Supplier

IOL Chemicals is an innovation-driven bulk drug, Intermediate and Specialty Chemicals company.

Contact Supplier

IKF/Pharmasynthese have been with fine chemicals market and APIs performance for more than 40 years.

Contact Supplier

medac CDMO: Tailored CDMO services for injectables in syringes, cartridges & vials – aseptic, reliable, flexible and a solution ahead.

Contact Supplier

Coral

Contact Supplier

ICE Pharma offers a unique range of bile acid products and best-in-class services for the pharmaceutical industry.

Contact Supplier

Infliximab

ACCESS ALL DATA, CHEMISTRY

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

12 API Suppliers, 1 JDMF, 7 NDC API, 5 Listed Suppliers

12 API Suppliers
1 JDMF
7 NDC API
5 Listed Suppliers

DEVELOPMENTS

71 Drugs in Development

71 Drugs in Development

FINISHED DOSAGE FORMULATIONS

217 FDF Dossiers, 6 FDA Orange Book, 16 Europe, 6 Canada, 185 Australia, 3 South Africa, 1 Listed Dossiers

217 FDF Dossiers
6 FDA Orange Book
16 Europe
6 Canada
185 Australia
3 South Africa
1 Listed Dossiers

DIGITAL CONTENT

1 Data Compilation #PharmaFlow, 157 News #PharmaBuzz

1 Data Compilation #PharmaFlow
157 News #PharmaBuzz

GLOBAL SALES INFORMATION

6 US Medicaid Prescriptions, 53 Annual Reports

6 US Medicaid Prescriptions
53 Annual Reports

MARKET PLACE

1 APIs, 7 FDF Dossiers

1 APIs
7 FDF Dossiers

PATENTS & EXCLUSIVITIES

5 Health Canada Patents

5 Health Canada Patents

Xls

Filters

Reset all filters

Filters

FILTER :

filter Company Reset all filters

5 All

01 2CELLTRION HEALTHCARE CANADA Limited

02 3Janssen Inc.

filter Patent Reset all filters

5 All

01 12106299

02 12261630

03 12324853

04 23028238

filter Product Reset all filters

5 All

01 2INFLIXIMAB

02 3Infliximab

filter Dosage Reset all filters

5 All

01 3Lyophilized Powder for Injection

02 2SOLUTION

filter Exp Date Reset all filters

5 All

01 22012-03-18

02 12017-08-01

03 22037-06-28

Product Main Page

01

Janssen Inc.

Infliximab

Organic Process R&D

Not Confirmed

Janssen Inc.

Organic Process R&D

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2012-03-18

Date Granted : 2001-02-06

Brand Name : REMICADE

Patent Number : 2106299

Filing Date : 1992-03-18

Strength per Unit : 100mg / vial

Dosage Form : Lyophilized Powder for Injection

Human Or VET : Human

Route of Administration : Intravenous

Patent Expiration Date : 2012-03-18

Date Granted : 2001-02-06

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

02

Janssen Inc.

Infliximab

Organic Process R&D

Not Confirmed

Janssen Inc.

Organic Process R&D

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2012-03-18

Date Granted : 2011-06-14

Brand Name : REMICADE

Patent Number : 2324853

Filing Date : 1992-03-18

Strength per Unit : 100mg / vial

Dosage Form : Lyophilized Powder for Injection

Human Or VET : Human

Route of Administration : Intravenous

Patent Expiration Date : 2012-03-18

Date Granted : 2011-06-14

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

03

Janssen Inc.

Infliximab

Organic Process R&D

Not Confirmed

Janssen Inc.

Country

Organic Process R&D

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2017-08-01

Date Granted : 2012-12-04

Brand Name : REMICADE

Patent Number : 2261630

Filing Date : 1992-03-18

Strength per Unit : 100mg / vial

Dosage Form : Lyophilized Powder for Injection

Human Or VET : Human

Route of Administration : Intravenous

Patent Expiration Date : 2017-08-01

Date Granted : 2012-12-04

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

04

CELLTRION HEALTHCARE CANADA ...

INFLIXIMAB

Organic Process R&D

Not Confirmed

CELLTRION HEALTHCARE CANADA Limited

Country

Organic Process R&D

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2037-06-28

Date Granted : 2024-01-02

Brand Name : REMSIMA SC

Patent Number : 3028238

Filing Date : 2017-06-28

Strength per Unit : 120 mg / mL

Dosage Form : SOLUTION

Human Or VET : Human

Route of Administration : SUBCUTANEOUS

Patent Expiration Date : 2037-06-28

Date Granted : 2024-01-02

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

05

CELLTRION HEALTHCARE CANADA ...

INFLIXIMAB

Organic Process R&D

Not Confirmed

CELLTRION HEALTHCARE CANADA Limited

Country

Organic Process R&D

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2037-06-28

Date Granted : 2024-01-02

Brand Name : REMSIMA SC

Patent Number : 3028238

Filing Date : 2017-06-28

Strength per Unit : 120 mg / mL

Dosage Form : SOLUTION

Human Or VET : Human

Route of Administration : SUBCUTANEOUS

Patent Expiration Date : 2037-06-28

Date Granted : 2024-01-02

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

Contact us
to update this info

Privacy policy
Terms and conditions
Disclaimers
Ask Us!